Gyre Therapeutics (GYRE) revenue breakdown
By product, Sales of Pharmaceutical Products is the largest at 99% of fiscal 2022 revenue.
Revenue by product
Fiscal years, as Gyre Therapeutics reports them in its 10-K filings; fiscal 2022 total $102M.
| Products | 2020 | 2022 | Share |
|---|---|---|---|
| Sales of Pharmaceutical Products | — | $101M | 99% |
| License of Intellectual Property | — | $1M | 1% |
| License | $15M | — | — |
| Collaboration | $6M | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GYRE.
Open GYRE in InvestinglyQuestions
Where does Gyre Therapeutics make its money?
In fiscal 2022, by product: Sales of Pharmaceutical Products $101M, License of Intellectual Property $1M.
From Gyre Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.